Alternative polyadenylation and miR‐34 family members regulate tau expression
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Tau pathologically aggregates in Alzheimer's disease, and evidence suggests that reducing tau expression may be safe and beneficial for the prevention or treatment of this disease. We sought to examine the role of the 3′‐untranslated region (3′‐UTR) of human tau mRNA in regulating tau expression. Tau expresses two 3′‐UTR isoforms, long and short, as a result of alternative polyadenylation. Using luciferase reporter constructs, we found that expression from these isoforms is differentially controlled in human neuroblastoma cell lines M17D and SH‐SY5Y. Several microRNAs were computationally identified as candidates that might bind the long, but not short, tau 3′‐UTR isoform. A hit from a screen of candidates, miR‐34a, was subsequently shown to repress the expression of endogenous tau protein in M17D cells. Conversely, inhibition of endogenously expressed miR‐34 family members leads to increased endogenous tau expression. In addition, through an unbiased screen of fragments of the human tau 3′‐UTR using a luciferase reporter assay, we identified several other regions in the long tau 3′‐UTR isoform that contain regulatory cis‐elements. Improved understanding of the regulation of tau expression by its 3′‐UTR may ultimately lead to the development of novel therapeutic strategies for the treatment of Alzheimer's disease and other tauopathies. image mRNA 3'‐untranslated regions (3'‐UTR) often regulate transcript stability or translation. Despite the centrality of the tau protein in Alzheimer's and other neurodegenerative diseases, the human tau 3'‐UTR has been little studied. This report identifies regions of the tau 3'‐UTR that influence expression and shows that microRNA (miR)‐34a targets this 3'‐UTR to lower expression, which is considered an important therapeutic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · cited 4×
“2007), PicTar (Krek et al. 2005), TargetScan (Lewis et al.”
MethodInfluentialAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474
Tau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · cited 2×
“…tau and neurodegenerative disease comes from the presence of dominant mutations of the microtubule-associated protein tau (MAPT) gene in rare familial cases of frontotemporal dementia with parkinsonism linked to chromosome 17 (Hutton et al. 1998; Poorkaj et al. 1998; Spillantini et al. 1998).”
BackgroundGoedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134 · cited 2×
“Profiling of the tau 3′-UTR isoform expression pattern by Northern blot has shown that the isoform expression pattern is tissue and cell type-specific (Goedert et al. 1988; Wang et al. 1993).”
Background
Cited by
Local Nucleation of Microtubule Bundles through Tubulin Concentration into a Condensed Tau Phase
Hernández-Vega, A., Braun, M., Scharrel, L., Jahnel, M., Wegmann, S., Hyman, B. T., Alberti, S., Diez, S., & Hyman, A. A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.042 · Cited by 395
“We hypothesize that in polarizing neurons, tau mRNA could be locally stabilized, producing tau protein at one side of the cell (Aronov et al., 2001; Dickson et al., 2013; Malmqvist et al., 2014).”
BackgroundThe p53/miR-34 axis in development and disease
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju003 · Cited by 354
miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo
Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., Dorval, V., Parsi, S., Morin, F., Planel, E., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv377 · Cited by 220
The role of extracellular Tau in the spreading of neurofibrillary pathology
Medina, M., & Avila, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00113 · Cited by 161
A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease
Reddy, P. H., Tonk, S., Kumar, S., Vijayan, M., Kandimalla, R., Kuruva, C. S., & Reddy, A. P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.067 · Cited by 143
The Regulation of microRNAs in Alzheimer's Disease
Kou, X., Chen, D., & Chen, N. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00288 · Cited by 112
Epigenetic memory: The Lamarckian brain
Fischer, A. (2014) · The EMBO Journal · doi:10.1002/embj.201387637 · Cited by 107
“…data suggest that elevated miR34 levels contribute to AD pathogenesis, a recent study found that inhibition of miR34a led to elevated TAU expression, suggesting that in such a context increasing rather than inhibiting miR34a should have therapeutic potential in AD (Dickson et al , 2013).”
microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases
Basak, I., Patil, K. S., Alves, G., Larsen, J. P., & Møller, S. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2093-x · Cited by 107
Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy
Iranifar, E., Seresht, B. M., Momeni, F., Fadaei, E., Mehr, M. H., Ebrahimi, Z., Rahmati, M., Kharazinejad, E., & Mirzaei, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27214 · Cited by 93
A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer’s Disease
Herrera-Espejo, S., Santos-Zorrozua, B., Álvarez-González, P., Lopez-Lopez, E., & Garcia-Orad, Á. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01676-9 · Cited by 81
UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation
Subramanian, M., Hyeon, S. J., Das, T., Suh, Y. S., Kim, Y. K., Lee, J.-S., Song, E. J., Ryu, H., & Yu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23597-9 · Cited by 62
Liu, Y., Zhang, Y., Liu, P., Bai, H., Li, X., Xiao, J., Yuan, Q., Geng, S., Yin, H., Zhang, H., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.11.004 · Cited by 45
RetractedDysregulation and Diagnostic Potential of microRNA in Alzheimer’s Disease
Pan, Y., Liu, R., Terpstra, E., Wang, Y., Qiao, F., Wang, J., Tong, Y., & Pan, B. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150451 · Cited by 29
The role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H.-J., & Ryu, J.-H. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 25
Comprehensive characterization of the transcriptional landscape in Alzheimer’s disease (AD) brains
Chen, C., Zhang, Z., Liu, Y., Hong, W., Karahan, H., Wang, J., Li, W., Diao, L., Yu, M., Saykin, A. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adn1927 · Cited by 12
“APA events in several genes, including COX2 ( 34 ), MAPT ( 35 ), and APP ( 36 ), were associated with AD.”
Alzheim(i)R: MicroRNAs in Alzheimer’s Disease
Barbato, C. (2014) · Journal of Cytology & Histology · doi:10.4172/2157-7099.1000e113 · Cited by 3
“MicroRNAs have been identified as regulators of key genes involved in Alzheimer’s Disease, including APP [16-18], BACE1 [19-23] and microtubule associated protein tau, MAPT [24-26].”
Metadata
- Authors
- Dickson, J. R., Kruse, C., Montagna, D. R., Finsen, B., & Wolfe, M. S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2013-09-18
- Volume
- 127
- Issue
- 6
- Pages
- 739-749
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2002759338
- Cited by
- 127
- References
- 16
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.